MIAMI, October 05, 2022--(BUSINESS WIRE)--OrganaBio’s LeukoPAC™ product line includes high quality cryopreserved leukopaks and PBMCs. Extensive donor and product characteristics are provided with every lot, and now researchers can access the cryopreserved inventory and select cells that best fit their specific requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005830/en/
Request a copy of our inventory report (Graphic: Business Wire)
Customers can view product inventory and choose products based on donor characteristics such as, gender, age, race, ethnicity, blood type, BMI, and smoking status. In addition to the infectious disease serology that is required by US FDA 21 CFR 1271, all donors are screened for CMV, EBV, WNV, and alloantibodies. High resolution genotyping by NGS is performed for HLA-A, B, C, DR, DQ, DP on all donors, and scientists can pick cell products from donors with common or rare HLA alleles.
An immunophenotyping profile allows customers to select material based on specific immune cell subset distribution, such as CD4:CD8 T cell ratio, B cells, monocytes, or NK cells composition. Contact us to receive the inventory report today!
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005830/en/
Dr. Priya Baraniak
Vice President of Corporate Development